Legend Biotech entered this earnings release as a pressured growth story, with the stock down sharply over the past three months. Today the mood shifted. Shares rose about 6% after the market absorbed a straightforward set of results. Q2 moved from a loss in Q1 to positive basic earnings per share and reported quarterly revenue of US$387.5m.

For a biotech widely viewed as long on promise and short on profits, that move into positive earnings on a quarterly basis is the key detail. The rest of the release either reinforces or challenges that signal.

Impressed by Legend Biotech’s move into positive quarterly earnings but still wary of the usual biotech profit swings? Check out 85 resilient stocks with low risk scores to compare this story with companies that pair growth potential with lower overall risk.

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs. Q2 2025: US$387.5m vs. US$255.1m (strong year on year increase)
• Net Income, Q2 2026 vs. Q2 2025: Net income of US$33.2m vs. net loss of US$125.4m (moved from loss to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.18 per share vs. a loss of US$0.68 per share (clear improvement in per share earnings)
• Pipeline Progress, Q2 2026 vs. Q2 2025: 14 products in Phase I, 1 in Phase II, 2 in Phase III vs. 11 in Phase I, 3 in Phase II, 3 in Phase III (shift in mix across clinical stages)

Prefer visual charts over dense blocks of financial text and clinical trial tables? Get a clear, at-a-glance view of Legend Biotech’s valuation, including how the market is pricing its move into positive quarterly earnings, with the full company report for Legend Biotech.

Legend Biotech: Bull Case Hinges On Execution Milestones

The bullish view on Legend Biotech centers on CARVYKTI as a large, durable franchise that can fund a broader cell therapy platform. Q2 goes a long way toward proving that is more than a story. CARVYKTI net trade sales of about US$657m and 50% year on year growth align with claims of strong physician and patient uptake, while 348 activated sites in 19 markets support the idea of widening access rather than a single market spike.

Profitability is also part of the thesis. Adjusted net income of US$63m and a move to positive basic EPS show that higher CARVYKTI volume is starting to translate into operating leverage, even after a recent equity raise. Finally, first in human proof of concept for in vivo CAR T cell therapy with LB2501 gives concrete support to the “platform, not single product” narrative that bullish investors highlight.

Compare Legend Biotech’s push into positive EPS and growing CARVYKTI sales with what the street expects next. See the consensus price target analysis for Legend Biotech to gauge whether analysts think this momentum lines up with their price targets.

Legend Biotech Bear Case: Concentration Risks Still Loom Large

The bearish view is that Legend Biotech is over reliant on CARVYKTI and that heavy spending and execution friction could keep profits choppy. Q2 does not fully clear that hurdle. CARVYKTI delivered US$657m in net trade sales and helped flip Legend into adjusted net income of US$63m, yet management still guides to quarter to quarter variability and only targets low to mid 50% gross margins for H2 2026, below the 75% long term ambition.

Bears also flag limited diversification and operational constraints. The pipeline produced encouraging early data, but revenues still hinge on a single product and a network of 348 sites that require complex logistics. The June equity raise and CEO resignation in July support concerns about governance and market structure risk rather than dispel them. The Q2 print weakens the most pessimistic profit arguments but leaves the concentration and execution worries largely intact.

Review Legend Biotech’s reliance on CARVYKTI, recent equity raise, leadership change and volatile share price, then systematically risk analysis for Legend Biotech which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If Legend Biotech’s shift into positive quarterly earnings has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the story develops. When you decide to take a position, keep your decisions clear with the Portfolio Command Center that cuts through noise and highlights the updates that matter most. For a broader view of sentiment and ideas, use the Community to tap into thousands of investor perspectives around Legend Biotech and its peers. This way you can spot potential catalysts and risks early and stay a step ahead of the market.

Seeking Fresh Alternatives Beyond Legend Biotech

Some stocks are already building breakout momentum while others are still under the radar for now. Spot fresh ideas before the crowd catches up and act now.

• Target reliable income streams and keep your portfolio flying steady with curated dividend payers screened through 8 dividend fortresses.
• Track the next wave of companies powering AI growth and catch early momentum shifts using the focused universe in 57 AI infrastructure stocks.
• Upgrade quality while others chase hype and focus on sturdier balance sheets with the carefully filtered group in list of solid balance sheet and fundamentals stocks (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.